Louisiana State Employees Retirement System Sells 900 Shares of Eli Lilly and Company $LLY

Louisiana State Employees Retirement System decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,500 shares of the company's stock after selling 900 shares during the quarter. Eli Lilly and Company makes up approximately 0.6% of Louisiana State Employees Retirement System's portfolio, making the stock its 17th largest position. Louisiana State Employees Retirement System's holdings in Eli Lilly and Company were worth $32,350,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company during the first quarter valued at about $27,000. Citizens National Bank Trust Department grew its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the first quarter valued at about $40,000. Finally, TD Capital Management LLC grew its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after buying an additional 31 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 0.1%

Shares of Eli Lilly and Company stock opened at $844.30 on Wednesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The company has a market cap of $799.09 billion, a price-to-earnings ratio of 55.18, a PEG ratio of 1.18 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company's 50-day moving average price is $736.97 and its 200-day moving average price is $766.03.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm posted $3.92 earnings per share. The company's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on LLY shares. Cantor Fitzgerald reduced their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 20th. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective on the stock. in a report on Sunday, August 17th. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $938.94.

Insider Transactions at Eli Lilly and Company

In other news, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.